Rakovina Therapeutics Inc ( (TSE:RKV) ) just unveiled an announcement.
Rakovina Therapeutics Inc. has strengthened its partnership with Variational AI following a successful $5.5 million financing round led by Nimbus Synergies and backed by Merck Global Health Innovation Fund, among others. This collaboration focuses on utilizing AI-powered generative models to accelerate the discovery of novel kinase inhibitors targeting DNA-damage response pathways, with promising preclinical results expected in 2025. The partnership exemplifies the transformative potential of AI in drug discovery, positioning Rakovina to advance precision oncology treatments and expand its AI-driven discovery efforts.
More about Rakovina Therapeutics Inc
Rakovina Therapeutics Inc. is a biopharmaceutical research company focused on developing innovative cancer treatments. The company leverages unique DNA-damage response technologies powered by Artificial Intelligence, specifically using their proprietary Deep-Docking™ platform, to accelerate the discovery and optimization of drug candidates. Rakovina aims to advance its distinctive DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners.
YTD Price Performance: -16.67%
Average Trading Volume: 354,982
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: C$15.62M
For a thorough assessment of RKV stock, go to TipRanks’ Stock Analysis page.